Lymphopenia can influence the prognosis of COVID-19 patients because it is a systemic manifestation of angiotensin-converting enzyme 2 (ACE2) receptors overexpression on the surface of lymphocytes and T-cells. Here, ACE2 is linked to lymphopenia.